OpenArc Corporate Advisory’s Colgate-Palmolive CL Stock Holding History

OpenArc Corporate Advisory’s Portfolio CL Stock Details CL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$911K	Buy	9,933 +2,538	+34%	+$222K	0.01%	366
2026 Q1	$630K	Buy	7,395 +1,122	+18%	+$100K	0.01%	396
2025 Q4	$496K	Buy	+6,273	New	+$492K	0.01%	402

Other funds holding CL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

OpenArc Corporate Advisory's CL Position: Q2 2026 in Review

OpenArc Corporate Advisory increased its Colgate-Palmolive (CL) stake by 34% in Q2 2026, buying an estimated $222K and bringing the position to 9,933 shares worth $911K. The position accounts for 0.01% of the portfolio, ranked #366.

OpenArc Corporate Advisory first reported a position in CL in Q4 2025 and has held it in 3 quarters since. 2,028 funds tracked by Wall St. Rank hold CL as of Q2 2026.

OpenArc Corporate Advisory held 9,933 shares of Colgate-Palmolive worth $911K as of Q2 2026.
OpenArc Corporate Advisory bought 2,538 Colgate-Palmolive shares in Q2 2026, an estimated $222K.
Colgate-Palmolive made up 0.01% of OpenArc Corporate Advisory's portfolio in Q2 2026, its #366 holding.
OpenArc Corporate Advisory first reported a position in Colgate-Palmolive in Q4 2025 and has held it in 3 quarters since.
2,028 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q2 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.